CYSTIC FIBROSIS 747 nebulizer). However, the adsorption rate in Figure 2C is still more rapid than that of vorkxed CLL dispersions in Figure 1 for the uniform fmal dispersion concentration (5 mg CLL/71 ml subphase) used (see "Materials and Methods"). This dilute concentration was chosen because it allow a disaimination between the adsorption isotherms of CLL (Si) and CLL (V). At h@m concentdona (z 0.25 mg/ml) vortexed CLL dqcrsions adsorb as rapidly as ch u m i d dispersions in Figure 2 
Sputum samples were obtpined from nkteen cystic fibrosis (CF) patients with respiratory tract infectiom due to Reuhnonm rrmrginasa and were exrmined for the presence of a specific local protective or blacking fador, which might partrally explain the inability of CF patients' pulmonary defense mechanisms to clear their lungs of Reudomonm infection. Using an assay that measures the bactericidal activity of fresh nonnd human sernm (FHS), eight-of nineteen CF sputa examined were capable of protecting either autdogous or heterdogous strains of P. uenrgtmccr from serum bactericidal activity. Most of this protective activity was absorbable at 4OC by P s e r r d o m , and could be reduced by dilution In phosphate buffered sdim or counteracted by an i~-crease in senun concentration. This protective activity is believed to be due to a Reudomomq-specific bactericidal blocking antibody. In contrast, only two of 17 non-CF sputa were found to significantly inbibit the bactericidal activity of FHS for P. aeruginosa Furthermore, three out of five CF sputa also protected Escherichiu eoh ' from the bactericidal activity of FHS. This protective activity was mucb less tbrn that observed with P. aerughosu, and was not absorbable at 4"C, suggesting the presence of a second blocking or protective factor in CF sputum. From these observatioos, we conclude that sputum from CF patients infected with P. aerughoaa contains one or more factors that interfere with the bactericidal activity present in FHS.
Abbreviations BHI, brain heart infusion CF, cystic fibrosis CFU, colony fonning unit FHS, fresh normal human serum PBS, plumphate buffered saline PIA, pseudomonas isolation agar sIgA, secretory IgA morbidity and mortaliiy in people with cystic fibroiis (CF). Although respiratory infection with Staphylococcur aureus often occurs, ~se;domo&s aetuginosa ( p~i & r l y the mucoid colonial form) eventually emerges as the dominant pathogen in 70-905b of CF patients, and > 90% die of progressive pulmonary insufftciency complicated by infection with P. aenrginosa (4) .
Except for respiratory tract infections, CF children are not more susceptible to infection than normal children of comparable age. P. aenrginosa is known to be an opportunistic pathogen, which commonly infects the debilitated patient (25, 26) , and is seldom isolated from pediatric patients with chronic respiratory disease other than CF (4, 11) . These basic clinical observations, coupled with the fact that pulmonary infections rarely spread outside the respiratory tract in CF patients, strongly suggest a defect in local pulmonary defense mechanisms.
Despite the presence of elevated levels of Pseudomonas antibodies in CF patients' sera and pulmonary secretions (13, 15) , these bacteria are not cleared by pulmonary defense mechanisms. Alveolar macrophages isolated from CF patients appear normal (B), but CF senun appears to interfere with the ability of rabbit and human alveolar macrophes to ingest and destroy Pseudomonas (2, 3, 5, 21, 23) . This effect has been attributed to either a serum deficiency (2), or a serum inhibitory factor (3, 21, 23 In addition to intdering with phagocytais, CF senun has also been found to block scnun bactericidal activity for P. aetuginosa. Whereas P. aeruginosa strains isolated from CF patients were more sensitive to the bactericidal activity of normal human serum than strains isolated from non-CF patients (12, and Schiller, N.L., manuscript in preparation), sera -from CF patients chronically infected with P. aetuninosa showed a selective inability in bactericidal activity aga&t the patient's own P. aetuginosa isolate, suggesting the presence of "bactericidal blocking" antibodies (12) . A similar heat-stable blocking factor has been detected in the serum of patients with chronic P. aeruginosa infection and characterized as IgG (8, 24) . Recently, Thomassen and Demko (22) identified the presence of a protective or blocking factor in sera from CF patients in poor clinical condition, and have suggested that the presence of this factor may contribute to the failure of CF patients to control infection.
The purpose of the present study was to examine the sputum of chronically infected CF patients for the presence of a serum bactericidal blocking factor. We reasoned that because infection with P. aeruginosa remains localized in the respiratory tract and is not cleared by pulmonary defense mechanisms, a factor@) that protects this microorganism from host defenses should be present in respiratory secretions. The results suggest that CF sputum contains one or more factors that interfere with the bactericidal activity of normal human serum. (20) scoring iystem, in which a maximal score of 25 points is awarded for each of four categories-chest roentgenogram, general activity, physical examination, and nutrition-for a best possible score of 100 points. Patients were classified by their physician into four categories as follows: (1) good clinical condition, total score of 80-100, moderate clinical condition, total score of 60-80; advanced clinical condition, total score of 40-60, and poor clinical condition, total score of (40. Sputum samples from seventeen non-CF patients (hospitalized with a variety of clinical conditions) were randomly selected and generously supplied by Drs. John Lewis and Ira Roy, Clinical Microbiology Laboratory, Loma Linda University Medical Center, Loma Linda, CA. Samples of sputum were kept frozen until ready for use.
MATERIALS AND METHODS

Sputum
Preparation of sputum samples. For these studies, each sample of sputum was fmt plated onto BHI Agar (BBL Microbiology Systems, Cockeysville, MD) and PIA (Difw Laboratories, Detroit MI) to isolate any bacterial species present. The sputum was then separated into the soluble and gel phases by emulsifying the sputum with a tissue homogenizer and centrifuging the emulsion at 120,000 x g for 4 h at 4°C. (Occasionally, a sputum sample had to be diluted first with PBS to provide enough volume for sample preparation). The supernatant was then filtered through a 0.45 pm filter and stored in small aliquots at -70°C.
Bacterial cultures. All strains of P. aeruginosa employed in these studies were isolated by this laboratory from the sputum of CF patients, and identified by gram-stain, oxidase reaction, pigment production, and growth on PIA and at 42°C. Where required, further ident*cation was accomplished using Flow Laboratories, Inc. N/F System (Flow Laboratories, Inc., Roslyn, NY). In addition, a mucoid strain of Escherichia coli was isolated from a CF patient sputum and generously provided to us by the Clinical Microbiology Laboratory at San Bernardino County Medical Center.
Serum bactericidal/blocking assay. Blood was obtained from five normal adult male volunteers (who have not been previously infected with P. aeruginosa) by venipuncture and allowed to clot at room temperature for 30 min. After centrifugation at 1000 X g for 15 min at 4"C, the serum was removed, pooled and either used immediately or stored at -70°C in small aliquots until ready for use. For this assay, Pseudomonas strains were grown overnight in BHI broth at 37"C, adjusted spectrophotometrically at 550 nm to a concentration of approximately 1 x 108 CFU/ml and then diluted in 0.01 M PBS, pH 7.4 to a final wncentration of 5 X 10' CFU/ml.
The following studies were done using 96-well tissue culture plates (Becton Dickinson and Co., Oxnard, CA). To each well was added 100 pl of either PBS or sputum (undiluted or serially diluted in PBS). After adding 50 pl of bacteria (5 x lo4 CFU/ml), the mixtures were incubated at 37°C for 30 min with gentle rotation using a Lab-Line Orbit Environ-Shaker (Lab-Line Instruments, Inc., Melrose Park, IL). Although preliminary experiments had suggested that this preincubation step increased blocking activity, further studies revealed that preincubation was not necessary for most experiments. Nevertheless for continuity with earlier experiments, all of the experiments described herein utilized this preincubation step.
After this preincubation step, 100 pl of either 3.13% FHS or PBS was added, and the mixtures were reincubated at 37°C for 60 rnin with gentle rotation. Afterwards, the tissue culture plate was placed on ice to stop any further reaction, and 100 pl and lop1 aliquots were removed from each well and plated onto BHI agar, incubated overnight at 37°C and the number of CFU/ml determined. As controls for each experiment, bacteria were incubated in PBS alone, in PBS with FHS, and in PBS with sputum. The number of bacteria in sputum + FHS was then compared to the number of bacteria in the sputum + PBS wntrol, and all values were then computed as % bacterial survival according to the following formula:
Absorption experiments. Overnight BHI broth grown cultures (at 37°C with agitation) were centrifuged at 7000 x g for 5 min; the pellet was resuspended in PBS and adjusted spectrophotometr i d y to a concentration of approximately 1 X 10' organisms/ml. For each ml of sputum to be absorbed, 3 x 10' organisms were centrifuged at 7000 x g for 5 min, the supernate discarded, and the pellet resuspended in sputum to yield a final concentration of approximately 3 x lo9 bacteria/ml sputum. This mixture was then tumbled end-over-end for 60 rnin at 4°C. Afterwards, the mixture was centrifuged at 7000 x g for 5 min, and the absorbed supernatant was then used to resuspend a second bacterial pellet and the absorption repeated. After the third absorption, the bacteriasputum mixture was then centrifuged at 25,000 x g for 60 rnin and the supernatant was filter sterilized through a 0.45 p filter. This absorbed sputum was either used immediately or stored in small aliquots at -70°C until ready for use. As a control, a sputum sample without bacteria was handled similarly and labeled as absorbed sputum control.
RESULTS
In a study to be described in detail elsewhere (Schiller, N. L., and R. A. Hatch, manuscript in preparation), the sensitivity of mucoid and nonmucoid strains of Pseudomonas aeruginosa to the bactericidal activity of FHS was compared. Whereas 88.5% of mucoid strains (23/26) were sensitive to 51.56% FHS (i.e., >90% of the organisms were killed at this serum concentration after incubation for 60 min at 37"C), only 14.8% of nonmucoid strains (9/61) were sensitive to 51.56% FHS. To ensure the detection of serum bactericidal blocking activity in CF sputum samples, only highly serum-sensitive mucoid strains (obtained from the sputum of CF patients) were employed in the studies described below.
The ability of CF sputum to protect P. aeruginosa from the bactericidal activity of FHS was examined. In each of these experiments, the survival of the test strain in the test sputum is first determined (CFU in 40% sputum/CFU in PBS); the number of CFU in sputum then serves as the wntrol for determining the % survival of the test strain in the presence of FHS and sputum (CFU in sputum + FHS/CFU in sputum + PBS). The results obtained using one CF sputum preparation are shown in Figure  1 . FHS, at wncentrations of 1.25% or higher, was bactericidal for Ps-D, a strain isolated from Sp-D sputum, with less than 1% survival routinely observed. The addition of W o Sp-D sputum completely blocked the killing activity of 1.25% FHS for Ps-D. This blocking activity was reduced when the serum concentration was raised from 1.25 to 10% FHS (as shown here), or when the sputum concentration was diluted in PBS (as illustrated in Figure  3 with S p K sputum).
Further studies were performed to determine whether this protective activity in CF sputum was limited to the strain@) isolated from that particular sputum. For these experiments, the blocking activity of four CF sputa, one non-CF sputum (infected with a nonmucoid strain of P. aeruginosa, Ps-L), and one non-CF, nonPseudomonas infected sputum (from a patient with allergic bronchitis) were examined using a battery of five test strains. Each of these strains was highly serum-sensitive in the absence of sputum. The results are presented in Figure 2 . Although in a few cases a particular sputum protected its autologous strain better than other strains (e.g., S p D and Ps-D), all five strains were protected from the bactericidal activity of FHS by each of these four sputa. The only exception was that S p K was directly bactericidal for Ps-I in the absence of FHS. In contrast to these CF sputa, SpM, the non-CF, non-Pseudomonas infected sputum did not protect any strain tested. Sp-L, the non-CF, Pseudomonas-infected sputum showed slight protective activity specifically for Ps-K. (Note: Ps-L was not serum-sensitive and could not be employed in this assay).
Nineteen CF sputum samples were obtained, and one or more muwid strains were isolated from 15 of these sputa. All nineteen CF sputa were then examined for blocking activity using either an autologous or heterologous Pseudomonas strain, and 18 of these CF sputa (94.7%) exhibited signif~cant protective activity (Le., > 20% bacterial survival). The results are shown in Table 1 . The blocking activity of 7 CF sputa for their autologous mucoid isolates is shown in the top portion of this table, and averaged 100.2% bacterial survival. The bactericidal blocking activity of the remaining 12 CF sputa was examined using heterologous strain Ps-P which was used for these studies because four of these sputa did not harbor a muwid Pseudomonas strain in the sputum sample examined (perhaps due to antibiotic chemotherapy) and the remaining five sputa were wlonized/infected with a muwid strain which was phenotypically unstable. The blocking activity of these 12 CF sputa are shown on the bottom portion of Table 1 (average 64.2% bacterial survival). Only one CF sputum was considered to be not significantly protective, Sp-T (12.6 f 9.79%). It is not known if this sputum would have been si@~cantly protective had higher sputum concentrations been available for examination. Table, it would appear that blocking activity is not d i i y related to clinical condition, because high levels of blocking activity were observed in patients in good (Sp-Q) as well as poor clinical condition (SpD).
From this
In contrast to the results with CF sputa, only two of 17 non-CF sputa examined for blocking activity using strain Ps-P were found to be si@cantly protective (i.e., >20% bacterial survival). Both of these sputa were heavily infected with Staphylococcus aureus and averaged 96.8% bacterial survival. Two non-CF, Pseudomonos-infected sputa were only slightly protective for Ps-P (average = 9% bacterial survival). Of the remaining 13 non-CF sputa, four had no blocking activity, and 9 were slightly protective (average -12.2% bacterial survival).
Five CF sputum samples (SpD, SpK, Sp-N, Sp-0, Sp-P) were also examined for protective activity for a muwid strain of Escherichia coli isolated from a CF sputum. Three of the sputa (Sp-D, S p N and SpO) demonstrated blocking activity for this strain.
This protective activity for E. coli, however, was usually much less than that for P. aeruginosa. For example, the % survival of P. aeruginosa strain Ps-N incubated in serum + Sp-0 sputum was 79.2 f 13.6%, whereas the % survival of E. coli incubated in serum + Sp-0 sputum was only 16.9 * 5.3%. Without Sp-0 sputum, however, there was no survival of either strain in 1.25% FHS.
Most of the protective activity present in CF sputum was ' All sputa were tested at a final concentration of 4096, except for SpG.
SpR, and S p U (20% sputum) and Sp-S and S p T (10% sputum). dctamhed to be removal by absorption of sputum with P. aenrginosa A representative experiment is shown in Figure 3 . The protective activity of S p K sputum for Ps-K was removed by preabsorption with Ps-K as shown using sputum concentrations of 209b or less. At 40% sputum, however, the absorbed and unabsorbed sputum samples were equally protective. Similar results were obtained when S p K was absorbed with Ps-D and when S p N was absorbed with Ps-N. In contrast, absorption of S p N or Sp-0 with E. coli did not reduce the protective activity of these sputa either for P. aerugitwsa strains or for E. coli. Furthermore, absorption of S p N with Ps-N did not reduce the protective activity of this sputum for E. coli although it ~i~c a n t l y reduced the protective activity for Ps-N. DISCUSSION The inability of CF patients to clear their lungs of P. aeruginosa infection, despite the presence of normal alveolar macrophages (23) and elevated levels of Pseudomonas antibodies in their sera and pulmonary secretions (13, IS), has prompted the search for a s p d c blocking Eactor(s) which might explain these observations. Whereas most studies have focused on CF sera, we chose to examine CF sputum to determine if a spedic local protective or blocking factor c d d be detected there. In addition we decided to use an assay which measures the bactericidal activity of FHS for mucoid strains of P. aeruginosa. This bactericidal activity is believed to be mediated primarily by IgG and/or IgM and the classical complement pathway (N. L. Schiller and M. J. Alazard, manuscript in preparation). This serum bactericidal assay was chosen for several reasons: (1) the essay can be performed with relatively small amounts of patient material, (2) one can monitor blocking activity affecting either or both antibody-or complement-mediated functions; and (3) the knowledge that a serum bactericidal blocking factor@) has previously been suggested or demonstrated to be present in CF serum (8, 12, 22, 24) .
Eighteen out of nineteen CF sputa examined were: capable of swcantly inhibiting the senun bactericidal activity of FHS for either autologous or heterologous strains of P. aeruginosa. In a few cases the best protection was demonstrated with an autologous sputum-muwid isolate combination, but in general this protective activity was usually nonstrain specific for Pseudomonas. In wntrast, only two of 17 non-CF sputa demonstrated comparable blocking activity for P. aeruginosa In a few cases, 40% CF sputum was directly cidal for a specific Pseudomonas strain. This cidal activity was usually only observed at the highest sputum wncentrations, and protective activity could often be observed at 20% sputum concentrations or below, or after the sputum had been exhaustively dialyzed with PBS.
When considering the probable serum bactericidal blocking factors in CF sputum, at least three possibilities come to mind. First, CF sputum might harbor blocking antibodies-sIgA, IgA, IgM, or IgG-that might bind to the bacterial cell surface and wmpete with serum bactericidal immunoglobulins. Several investigators have previously delineated the existence of "bactericidal blocking" antibodies (8, 12, 22, 24) characterized as IgG (8,24) in CF serum. Second, CF sputum might contain bacterial cellular components-slime, lipopolysaccharide, outer membrane proteins, etc.-that might tie up serum bactericidal antibodies and f u wmplement (i.e., immune complexes). There have been several reports of immune complexes, both in sera (1, 14) and sputum (18) of CF patients. Finally, CF sputum might have bacterial or host-derived enzymes-protease, elastase, Lipase, etc.-that might inactivate wmplement or degrade the bactericidal immunoglobulin target(s) on the bacterial cell surface. It should be noted that Schultz and Miller (19) have reported that the Pseudomonas extracellular enzyme, elastase, can directly inactivate wmplement.
Our results seem to implicate the presence of at least two serum bactericidal blocking factors. Most, but not all, the blocking activity in CF sputum was absorbable at 4°C with Pseudomonas. This blocking activity could be reduced by dilution of sputum with PBS or counteracted by raising the serum concentration from 1.25 to 10% or higher. These observations suggest that this blocking factor can attach to the bacterial surface and can wmpete with the bactericidal factor(s1 Dresent in FHS. We believe that this factor is a ~seudornon&-~~cific bactericidal blocking antibody. It should be noted that all of the CF sputum samples examined in these studies were obtained from patients chronically colonized/ infected with P. aeruginosa and hence expected to contain antiPseudomonas immunoglobulins (13, 15) . The presence of IgA and IgG antibodies against surface antigens of P. aeruginosa in sputum has been previously described (17) . Furthermore, Hann and Holsclaw (10) demonstrated that all strains of P. aemginosa recovered from sputum specimens of CF patients were coated with antibodies of IgA, IgG, and IgM classes. Of speclftc interest was their observation that the most intense coating of the bacterial surface was with IgA. Because IgA does not ordinarily fm wmplement or promote phagocytosis, its binding to bacterial surfaces may interfere with the binding of bactericidal IgG or IgM antibodies. IgA has been shown to block the binding of IgG to antigen (7.9) and the complement-mediated lysis of Neisseria meningitidb (6) and IgG-sensitized erythrocytes (16) , possibly by sterically hindering the deposition of activated wmplement components on the target cells. Considering the fact that sIgA would be expected to be elevated in these infected CF sputum samples, and its potential for inhibiting serum bactericidal reactions, we suggest that part of the Pseudomonas protective activity in CF sputum is due to "bactericidal blocking" antibodies of the sIgA class. The specificity of these "bactericidal blocking" antibodies might also explain the higher levels of blocking actiGty observed when autologous sputa and mucoid isolate combinations were used. Preliminary studies in this laboratory have detected blocking activity in adcolumnfractionated sputum pool containing sIgA but not IgG (N. L. Schiller, unpublished observations). Further studies to characterize this blocking factor in CF sputum are in progress. In addition, it will be of interest to determine if this blocking factor can also interfere with the opsonization and/or phagocytosis of P. aeruginosa by alveolar macrophages. Several investigators have previously described such blocking activity in CF sera (2, 3, 5, 21, 23) .
In three of five CF sputa, E. coli was also slightly protected from serum bactericidal activity, although at a much lower level than P. aeruginosa Unlike the P. aeruginosa protective factor, however, this blocking activity was not absorbable at 4°C. This might suggest the presence of a second factor, which nonspecifically inhibits antibody and wmplement-mediated bacteriolysis.
The presence of a second factor might also explain the residual protective activity for P. aeruginosa observed in CF sputum after absorption with Pseudomonas, as well as the low-level blocking activity observed in eleven non-CF sputa (it may not explain, however, the two non-CF sputa with significant blocking activity). Preliminary studies in this laboratory have demonstrated that the incubation of CF sputum with FHS for 60 min at 37°C markedly reduces the complement hemolyticso titers of FHS (N. L. Schiller and R. L. Millard, unpublished observations). Similar results were obtained when filter-sterilized culture filtrates of P. aeruginosa were incubated with FHS (N. L. Schiller and R. L. Millard, unpublished observations). It is not known whether this complement depletion represents complement activation and wnsumption (either through antibody-antigen-complement activation or direct antigen-complement activation) or complement degradation (such as direct complement enzymatic inactivation). Further studies are needed to establish the identity and source of this second blocking factor in CF sputum, and to determine if it is related to the complement depleting activity detected in Pseudomonas culture filtrates.
In summary, eighteen of nineteen sputum samples obtained from CF patients chronically colonized/infected with P. aeruginosa were found to contain one or more factors which interfered with the bactericidal activity of FHS. One factor was absorbable by P. aeruginosa and is believed to be a Pseudomonas-s@ic bactericidal blocking antibody. The presence of Pseudomonas protective activity in CF sputum might be expected to interfere with pulmonary defense mechanisms and partially explain why CF patients are usually unable to clear this microorganism from their lungs.
